Solriamfetol in excessive daytime sleepiness: a profile of its use
, 2020 Compliance with Ethical Standards Disclosure: The preparation of this review was not supported by any external funding. Conflicts of interest: Emma Deeks and Young-A Heo are salaried employees of Adis International Ltd./Springer Nature, are ...
Young-A Heo (6594442) +1 more
core +1 more source
, 2023 Declarations Funding The preparation of this review was not supported by any external funding. Authorship and Conflict of interest Sheridan M. Hoy is a salaried employee of Adis International Ltd/Springer Nature, and declares no relevant conflicts of ...
Sheridan M. Hoy (4897468)
core +1 more source
Comparative Efficacy and Safety of Multiple Wake-Promoting Agents for the Treatment of Residual Sleepiness in Obstructive Sleep Apnea Despite Continuous Positive Airway Pressure: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials. [PDF]
CNS DrugsBackground and objectivesResidual sleepiness can occur in adult patients with obstructive sleep apnea (OSA) despite adequate treatment with continuous positive airway pressure (CPAP).
Tanayapong P +6 more
europepmc +2 more sources
, 2020 Introduction Excessive daytime sleepiness (EDS) in patients with obstructive sleep apnea (OSA) is associated with an increased risk of driving accidents.
Vermeeren, A. +13 more
core +1 more source
Incidence and duration of common early-onset adverse events in randomized controlled trials of solriamfetol for treatment of excessive daytime sleepiness in obstructive sleep apnea and narcolepsy [PDF]
, 2022 STUDY OBJECTIVES: This post hoc analysis characterized the weekly incidence and overall duration of common early-onset, treatment-emergent adverse events (TEAEs) during solriamfetol treatment. METHODS: Participants (obstructive sleep apnea [OSA], n = 474;
Schweitzer, Paula +12 more
core +1 more source
Psychomotor Vigilance Performance in Participants with Excessive Daytime Sleepiness in Obstructive Sleep Apnea or Narcolepsy Compared with SAFTE-FAST Model Predictions [PDF]
, 2022 IntroductionExcessive daytime sleepiness (EDS) associated with narcolepsy or obstructive sleep apnea (OSA) can impair vigilance/attention. Solriamfetol, a dopamine/norepinephrine reuptake inhibitor, is approved to treat EDS associated with narcolepsy (75-
Vonk, P.E. +15 more
core +4 more sources
Impaired Alertness Correlates With Chronic Anxiety: A Prospective Tertiary University Centre Cohort
Journal of Sleep Research, EarlyView.ABSTRACT The Maintenance of Wakefulness Test (MWT) is a widely used objective measure of daytime alertness, especially in patients with sleep disorders at increased risk of accidents. Anxiety and depression are common in this population and may influence subjective sleepiness and objective alertness.
Anice Borjon +13 more
wiley +1 more source
Nature and Science of Sleep, 2020 Emily C Barker,1 Julie Flygare,2 Shalini Paruthi,3,4 Katherine M Sharkey5– 7 1Case Western Reserve University School of Medicine, Department of Pediatrics, Cleveland, OH, USA; 2Project Sleep, Los Angeles, CA, USA; 3Sleep Medicine and Research ...
Barker EC +3 more
doaj
Journal of Sleep Research, EarlyView.Orexin 2 receptor agonists have demonstrated that targeting the orexin system may address symptoms of central disorders of hypersomnolence. Results of this phase 1 study support the phase 2 clinical evaluation of oral alixorexton in patients with IH, NT2 and NT1.
Ronald R. Grunstein +10 more
wiley +1 more source
Recent advances in treatment for narcolepsy
Therapeutic Advances in Neurological Disorders, 2019 Narcolepsy type 1 (NT1) is a chronic orphan disorder, caused by the selective and irreversible loss of hypocretin/orexin (ORX) neurons, by a probable autoimmune process.
Lucie Barateau, Yves Dauvilliers
doaj +1 more source